Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis

Dipeptidyl-peptidase-4 inhibitors (DPP4i) have been the most used antidiabetic medications worldwide due to their good safety profiles and tolerability with a low risk of hypoglycemia, however, large cardiovascular outcome trials (CVOTs) have not shown any significant the prognostic superiority. On...

Descripción completa

Detalles Bibliográficos
Autores principales: Chikata, Yuichi, Iwata, Hiroshi, Miyosawa, Katsutoshi, Koike, Takuma, Yasuda, Hidetoshi, Funamizu, Takehiro, Doi, Shinichiro, Endo, Hirohisa, Wada, Hideki, Naito, Ryo, Ogita, Manabu, Dohi, Tomotaka, Kasai, Takatoshi, Isoda, Kikuo, Okazaki, Shinya, Miyauchi, Katsumi, Minamino, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948237/
https://www.ncbi.nlm.nih.gov/pubmed/35332212
http://dx.doi.org/10.1038/s41598-022-09059-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948237/
https://www.ncbi.nlm.nih.gov/pubmed/35332212
http://dx.doi.org/10.1038/s41598-022-09059-2

Ejemplares similares